What is the clinical evidence from this study?

Study design: Case Report. Population: Advanced cystic lung cancer complicated with pulmonary lymphangitic carcinomatosis (n=1). Intervention: Palliative surgery, chemotherapy, and immunotherapy. Primary outcome: Survival.

What question did this study set out to answer?

To describe the diagnosis and multimodal clinical management of advanced cavitary lung adenocarcinoma complicated by pulmonary lymphangitic carcinomatosis and malignant pericardial effusion.

June 8, 2026Journal of Cardiothoracic SurgeryOpen Access

Advanced cystic lung cancer complicated with pulmonary lymphangitic carcinomatosis: a case report

View Full Paper

Ask AI

Bookmark

Key result

Palliative surgery, chemotherapy, and immunotherapy yield 41-month survival in an advanced cystic lung cancer case.

Why the study?

Pulmonary lymphangitic carcinomatosis carries a poor prognosis with no definitive therapy, frequently presenting at an advanced stage.

Design

Case report

Follow-up

41 months

Authors

HTHuizhen TangSeventh People's Hospital of Shanghai JZJiayi ZhouSeventh People's Hospital of Shanghai TTTianning TianSeventh People's Hospital of Shanghai

Discussion

Member takes

Implication

Should not change PLC management; leaves open whether multimodal therapy extends survival in advanced lung adenocarcinoma.

Key Points

To describe the diagnosis and multimodal clinical management of advanced cavitary lung adenocarcinoma complicated by pulmonary lymphangitic carcinomatosis and malignant pericardial effusion.
Evaluated a single patient presenting with stage IVA (pT3N2M1a) right upper lobe cavitary lung adenocarcinoma and pulmonary lymphangitic carcinomatosis.
Performed palliative video-assisted thoracoscopic right upper lobe wedge resection with pericardial windowing followed by six cycles of pemetrexed and carboplatin alongside four cycles of pembrolizumab.
Pathology and molecular testing demonstrated adenocarcinoma with 80% solid components, positive PD-L1 expression (TPS of 55%), and negative driver gene mutations (EGFR, ALK, ROS1).
Immune-related colitis presenting as hematochezia was successfully managed and resolved using intravenous followed by oral methylprednisolone maintenance therapy.
The patient maintained stable general condition without obvious tumor progression, reaching an overall survival of 41 months as of the last follow-up.

Study Design

Type

Case Report (n=1)

Structured PICO

Population

A 63-year-old male with advanced cystic lung adenocarcinoma complicated by pulmonary lymphangitic carcinomatosis and pericardial metastasis, followed for 41 months.

Intervention

Palliative surgery followed by sequential chemotherapy and immunotherapy

Outcome

Survivalhard clinical

Palliative surgery followed by sequential chemotherapy and immunotherapy may provide prolonged survival in patients with advanced cavitary lung adenocarcinoma complicated with pulmonary lymphangitic carcinomatosis.

Cite This Study

Tang et al. (2026) conducted a case report in Advanced cystic lung cancer complicated with pulmonary lymphangitic carcinomatosis (n=1). Palliative surgery, chemotherapy, and immunotherapy was evaluated on Survival. A patient with advanced cystic lung cancer and pulmonary lymphangitic carcinomatosis survived for 41 months following palliative surgery, chemotherapy, and immunotherapy.

synapsesocial.com/papers/6a265ee3ad53cfb9357c65d3 https://doi.org/10.1186/s13019-026-04299-z

View Full Paper

Ask AI

Bookmark

Advanced cystic lung cancer complicated with pulmonary lymphangitic carcinomatosis: a case report

Discussion

Member takes

Implication

Key Points

Study Design

Structured PICO

Cite This Study

Advanced cystic lung cancer complicated with pulmonary lymphangitic carcinomatosis: a case report

Discussion

Member takes

Implication

Key Points

Study Design

Structured PICO

Cite This Study

Also Consider

Also Consider